Here are the results of our members‘ survey from January:
- Our monthly newsletter is rated essential by 55%, nice to have by 44%, and unnecessary by 1%.
- Cooperation with majorEuropean conferences and trade fairs, combined with a discount for EBN members, is essential for 52%, nice to have for 41% and unnecessary for 7%.
- The free subscription of the „European Biotechnology Magazine“ is considered essential by 70%
another 29% voted for nice to have, and 1% for unnecessary.
- An EBN office in Brussels with contact to the EU consider 49% as essential, 42% as nice to have and 9% consider it unnecessary.
- For an annual „European Biotechnology Network Convention“ 42% voted with essential, 49% found it nice to have and 8% considered it unnecessary.
The many individual proposals for future activities of the network were very interesting. Our thanks to all the members for their participation. The following wishes were mentioned frequently:
- promoting of SMEs
- creating links between academia and industry
- workshops about different topics, e.g. clinical development, enzymes, software development etc.
- more virtual networking opportunities, online forum for members
- a directory of members- information and activities about funding opportunities and consortium building- a free company database
It is easy to understand that there is a great need for information and for opportunities for increased interaction between our members. We see two main difficulties:
- Frequently desired services such as funding opportunities and consortium building are both time-consuming and personnel-intensive and therefore hardly affordable for a network whose individual membership is free of charge.
- Data protection obliges us to treat the data of our members confidentially, in order to protect them from undesirable advertising. Even a passing on to the members themselves seems hardly possible at the moment, because advertisers can of course log in as a free member themselves and thus could gain free access to the data treasure.
09.03.2017: New issue of the Membership Magazine
Recently, you should have received the Spring Edition of our member journal „European Biotechnology Magazine“. We hope that you will appreciate the latest articles on digitalising insurance, EPO‘s fast-paced patent examination, the biomanufacturing of fragrances and flavors, the DNA phenotyping revolution in criminal investigation and, last but not least, pharma packaging.
15.03.2017: The European Biotechnology Science & Industry Guide 2017 was published by our member BIOCOM AG
This new book provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry. In addition to the detailed portraits on about ca. 170 pages, the 7th edition contains a summary of BIOCOM‘s latest report "Analysis of European biotech companies on the stock markets: US vs Europe". Readers will discover many success stories and current trends in the European biotech industry. Some of our Corporate Members have choosen the opportunity to participate for free and took advantage of the two-page company profile for a Europe-wide presentation.
03.11.2015: PwC launches study into management of scientific partnerships
The need to fill development pipelines is driving the development of novel partnership models within the pharma sector and this brings challenges for all participants. Building on its extensive work within the development of scientific partnerships, EBN Corporate Member PricewaterhouseCoopers Advisory N.V., is launching a detailed study into all aspects of partnership development and management, including key challenges and best practises within relationships between biotech, pharma and universities. EBN and its Corporate Members will contribute to the study and support the development of outcomes critical to successful scientific collaboration.
30.10.2015: Leitat leads H2020 project for improved cancer diagnosis and treatment –
The GLAM project
The project Glass-Laser Multiplexed Biosensor, GLAM for short, will use ground breaking technology to develop a device that is a step towards truly personalized medicine. The photonic-based point-of-care device will help oncologists make better treatment decisions according to the patient’s needs in a non-invasive manner for cancer diagnosis.
Specifically, GLAM will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a non-invasive manner, focusing on urine and genitourinary cancers. The project will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost.
Last, the unique GLAM technology will have the potential to be used with other types of biofluids, opening the way to the diagnosis and monitoring of other kinds of cancer and many more diseases.
“Most cancer biopsies must be analyzed in specialized laboratories, which involves high costs and long waiting periods, as they require specialised personnel and equipment,” says Izabel Alfany, project coordinator. “There is therefore a real need and urgency to have new devices that provide diagnosis, prognosis, and data monitoring faster and with exceptional ultra-sensitivity,” says Francesc Mitjans research project director at Leitat Technological Centre.
15.09.2015: University of Nottingham awarded RISE project
The University of Nottingham School of Pharmacy has been awarded a RISE project from H2020 (FutForm), with the aim to reduce the times and costs associated with medicine development, through the development of approaches to better predict and/or optimize the behaviour of actives and their formulations at an earlier stage of development. Recent research within the School of Pharmacy (University of Nottingham (UoN)) has focussed on the application of advanced surface analytical and biophysical tools to address this need. This proposal will build on this activity via an inter-sectoral researcher exchange program focussed on supporting future pharmaceutical formulations development.
The principal objective of FutForm is to translate the advanced analytical approaches developed at Nottingham, so that they become embedded into industrial practice for the development of future pharmaceutical processes and therapies. This will be achieved through a collaborative programme of researcher secondments with three small-medium enterprise (SME) companies, each with early stage innovative technologies in areas of importance to the future pharmaceutical industry, namely; enzyme formulations for improved cell isolation (Abiel s.r.l; Italy), nanoparticle platform formulations for oral and topical drug delivery (Inovapotek, Pharmaceutical Research and Development Lda; Portugal) and hydrogel formulations for cell-delivery (Hy2Care b.v.; Netherlands).
01.06.2015: University of Barcelona published in Nature for anti-infective development
The University of Barcelona, through Professor Francesc Rabanal has achieved publication in nature with his paper “A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity”. As one of the original partners in the IMI project ENABLE, Professor Rabanal has been developing a novel peptide with high potential for development to clinic.
04.05.2015: European Association for the Study of Obesity hosts 2015 annual meeting
EBN Member and Strategic Partner EASO (European Association for the Study of Obesity) hosted its annual meeting in Prague– bringing together Europe’s largest gathering of research and clinical practice around the prevention and management of obesity and associated diseases.
01.04.2015: Redx joins AIM
We are delighted to congratulate member company, Redx Pharma, on its recent Admission to AIM and £15m placing.
Redx joins AIM with a market capitalisation of over £55m and will be using the funds raised in its placing to progress the Group’s current pipeline of oncology and infectious disease assets. The funds will also support the launch of Redx’s third subsidiary which will focus on immunology.
Neil Murray, Chief Executive Officer of Redx, said: "This is a landmark moment for Redx and I am delighted to see the Company embarking on its next stage of development - prospects are exciting. We already have a pipeline of potential drug candidates focused on areas of high unmet need in cancer and infection. At the same time, we have secured partnerships and collaborations with AstraZeneca, the NHS, Pierre Fabre and others, which demonstrate our world-class credentials. The new funds raised will support the ongoing development of our pipeline as well as the launch of a third therapeutic area focused on immunology. Meanwhile our objective of the Company attaining early profitability remains."
31.03.2015 - TRN brings gram-negative programme to the IMI ENABLE project
TRN – The Research Network Ltd. has become a member of the IMI ENABLE Consortium, effective from January 1st 2015. TRN will work within the ENABLE consortium to progress a novel gram-negative antibiotic programme originating from international academic research.
Andy McElroy, TRN CEO, said “We have been working closely with the ENABLE consortium since its inception to assess a novel antibiotic approach which has high potential for direct-action against gram negative pathogens. We are delighted to formally join the ENABLE consortium to develop and validate this programme through to the clinic with leading European academic and industry partners”.
Membership - Join the Network!
Basic Membership for natural persons is free, while Advanced Membership for professionals including premium services costs only €100 p.a.
Click here to apply for network membership!
European Biotechnology Network AISBL
Rue de la Science 14b
1040 Brussels, Belgium
Tel: +32 2 588 70 71